Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.
Schönfelder S, Schirmbeck F, Waltereit R, Englisch S, Zink M.
Clin Neuropharmacol. 2011 Nov-Dec;34(6):256-7.
Related citations
Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
Yeh YW.
Clin Neuropharmacol. 2011 Jul-Aug;34(4):135-6.
Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.
Lee JS, Ahn JH, Lee JI, Kim JH, Jung I, Lee CU, Lee JY, Lee SI, Kim CY.
Clin Neuropharmacol. 2011 Sep-Oct;34(5):186-90.
Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, Weizman A, Ritsner MS.
Clin Neuropharmacol. 2011 Jul-Aug;34(4):155-60.
Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage.
Almeida J, Serrão EM, Almeida AT, Afonso JG.
Clin Neuropharmacol. 2011 May-Jun;34(3):131-2.
Neurobiological background for the development of new drugs in schizophrenia.
López-Muñoz F, Álamo C.
Clin Neuropharmacol. 2011 May-Jun;34(3):111-26. Review.
A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia.
Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty TK, Gangadhar BN.
Clin Neuropharmacol. 2010 Nov-Dec;33(6):288-92.
Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S.
Clin Neuropharmacol. 2010 Nov-Dec;33(6):271-5.
An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
Anand R, Geffen Y, Vasile D, Dan I.
Clin Neuropharmacol. 2010 Nov-Dec;33(6):297-302.
Bupropion for depression in schizophrenia.
Englisch S, Inta D, Eer A, Zink M.
Clin Neuropharmacol. 2010 Sep-Oct;33(5):257-9.
Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy.
Englisch S, Enning F, Grosshans M, Marquardt L, Waltereit R, Zink M.
Clin Neuropharmacol. 2010 Sep-Oct;33(5):227-9.
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.
Gilles M, Hentschel F, Paslakis G, Glahn V, Lederbogen F, Deuschle M.
Clin Neuropharmacol. 2010 Sep-Oct;33(5):248-9.
Salivary flow rate in patients with schizophrenia on clozapine.
Praharaj SK, Jana AK, Goswami K, Das PR, Goyal N, Sinha VK.
Clin Neuropharmacol. 2010 Jul;33(4):176-8.
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J, Bahk WM, Cho HS, Jeon YW, Jon DI, Jung HY, Kim CH, Kim HC, Kim YK, Kim YH, Kwon JS, Lee SY, Lee SH, Yi JS, Yoon BH, Kim SH.
Clin Neuropharmacol. 2010 Jul;33(4):169-75.
Effectiveness and safety of milnacipran treatment for a patient with delusional disorder, somatic type taking multiple medications for concomitant physical diseases.
Otani K, Miura Y, Suzuki A, Kinoshita O.
Clin Neuropharmacol. 2010 Jul;33(4):212-3.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on